The NFTI-QOL: A disease-specific quality of life questionnaire for neurofibromatosis 2

Journal of Neurological Surgery, Part B: Skull Base

Volumn 73, Issue 2, 2013, Pages 104-111

  Hornigold, Rachael E ^a   Golding, John F ^b   Leschziner, Guy ^a   Obholzer, Rupert ^a   Gleeson, Michael J ^a   Thomas, Nick ^a,c   Walsh, Daniel ^a,d   Saeed, Shakeel ^a,d   Ferner, Rosalie E ^a,e  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

EuroQOL; Neurofibromatosis 2; NFTI QOL; Quality of life; SF 36; Vestibular schwannoma

Indexed keywords

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; AGED; ANXIETY; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DISEASE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE; DIZZINESS; FACIAL NERVE PARALYSIS; FEMALE; HEARING; HUMAN; MALE; MENTAL HEALTH; MIDDLE AGED; NEUROFIBROMATOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; SHORT FORM 36; SOCIAL INTERACTION; SOLITARY VESTIBULAR SCHWANNOMA; VALIDATION STUDY; VISUAL ANALOG SCALE; WALKING; YOUNG ADULT;

EID: 84892660517     PISSN: 2193634X     EISSN: 21936331     Source Type: Journal    
DOI: 10.1055/s-0032-1301396     Document Type: Article

References (15)

1. Evans DGR, Howard E., Giblin C., et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A: 2010; 152A 2 327 332
2. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol: 2007; 6 4 340 351 (Pubitemid 46367948)
3. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H., Evans DG. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology: 2002; 59 11 1759 1765 (Pubitemid 35424459)
4. Plotkin SR, Stemmer-Rachamimov AO, Barker FG II., et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med: 2009; 361 4 358 367
5. Mautner VF, Nguyen R., Kutta H., et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-oncol: 2010; 12 1 14 18
6. Ammoun S., Flaiz C., Ristic N., Schuldt J., Hanemann CO. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res: 2008; 68 13 5236 5245
7. Fayers PM, Machin D. Quality of Life. 2nd ed. Wiley: 2007
8. Neary WJ, Hillier VF, Flute T., Stephens SD, Ramsden RT, Evans DG. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol: 2010; 35 4 291 299
9. Patel CM, Ferner R., Grunfeld EA. A qualitative study of the impact of living with neurofibromatosis type 2. Psychol Health Med: 2011; 16 1 19 28
10. Ware JE, Snow KK, Kosinski M., Gandek B. SF-36 Health survey. Manual & Interpretation Guide: 1993
11. The Euroqol Group EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy: 1990; 16 3 199 208
12. Kissil JL, Blakeley JO, Ferner RE., et al. What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers. Am J Med Genet A: 2010; 152A 2, Issue 2 269 283
13. Kind P., Dolan P., Gudex C., Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ: 1998; 316 7133 736 741 (Pubitemid 28121072)
14. Jenkinson C., Layte R., Wright L., Coulter A. The UK SF-36: An Analysis and Interpretation Manual. University of Oxford: 1996
15. Bronstein AM, Golding JF, Gresty MA., et al. The social impact of dizziness in London and Siena. J Neurol: 2010; 257 2 183 190